• In February 2026, Halozyme Therapeutics reported Q4 and full-year 2025 results showing revenue rising to US$451.77 million for the quarter and US$1.40 billion for the year, but a quarterly net loss of US$141.59 million driven in part by a US$48.70 million intangible asset impairment.
• Despite the earnings miss linked to acquisition-related costs and write-downs, Halozyme reaffirmed 2026 revenue guidance of US$1.71 billion to US$1.81 billion, underscoring management’s confidence in its ENHANZE-powered, partnership-focused growth model.
• We’ll now examine how Halozyme’s strong revenue growth but impairment-driven quarterly loss reshapes its investment narrative built around ENHANZE partnerships.

Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 30 best rare earth metal stocks of the very few that mine this essential strategic resource.

Halozyme Therapeutics Investment Narrative Recap

To own Halozyme, you need to believe in the durability of its ENHANZE royalty model and its ability to broaden partner usage, even as healthcare systems push harder on costs. The Q4 loss, driven by a US$48.7 million impairment and acquisition-related charges, is a setback but does not fundamentally alter the near term catalyst around ENHANZE partner launches or the key risk of revenue concentration in a few blockbuster collaborations.

The reiterated 2026 revenue guidance of US$1.71 billion to US$1.81 billion is the announcement that ties most directly to this earnings print. It shows management is holding its line on expected top line progress despite the impairment and EPS miss, which matters for how you weigh the strength of ENHANZE-driven royalties against the ongoing risks from patent challenges, pricing pressure, and dependence on a narrow partner base.

Yet beneath the headline revenue growth, investors should be aware that...

Halozyme Therapeutics' narrative projects $2.0 billion revenue and $1.1 billion earnings by 2028.

Uncover how Halozyme Therapeutics' forecasts yield a $77.12 fair value, a 4% downside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were previously modeling Halozyme to reach about US$2.2 billion of revenue and US$1.1 billion of earnings by 2028, so if you are weighing that view against the fresh impairment charges and ENHANZE patent and partner concentration risks, it is worth recognizing that these bullish scenarios are far more optimistic than consensus and could be revised as the impact of Q4’s loss and acquisitions becomes clearer.

Explore 9 other fair value estimates on Halozyme Therapeutics - why the stock might be worth over 2x more than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Halozyme Therapeutics research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Halozyme Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Halozyme Therapeutics' overall financial health at a glance.

No Opportunity In Halozyme Therapeutics?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 26 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• We've uncovered the 13 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Uncover the next big thing with 31 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.